Hiroshi Nagano

Title: Hiroshi Nagano: Innovator in Diabetic Maculopathy Treatment

Introduction

Hiroshi Nagano is a prominent inventor based in Nagoya, Japan. He has made significant contributions to the field of medicine, particularly in the treatment of diabetic maculopathy. With a total of 2 patents, his work focuses on developing effective therapeutic agents for this condition.

Latest Patents

Nagano's latest patents include a prophylactic or therapeutic agent for diabetic maculopathy. This agent can be administered for an extended period and exhibits efficacy through a mechanism that differs from existing medications. The invention involves a compound represented by a specific general formula, where X can be a halogen or hydrogen atom. The active ingredients, R and R, can represent hydrogen or an optionally substituted C1 to C6 alkyl group. Additionally, R and R can combine with a nitrogen atom to form a 5- to 6-membered heterocycle. A preferred compound in this invention is (2S,4S)-6-fluoro-2',5′-dioxospiro[chroman-4,4′-imidazolidine]-2-carboxamide. Furthermore, the invention provides a model animal with diabetic maculopathy, created by subjecting a diabetic animal to intraocular ischemia/reperfusion, which expresses edema in the retinal visual cell layer or in the macula lutea.

Career Highlights

Hiroshi Nagano is associated with Sanwa Kagaku Kenkyusho Co., Ltd., where he continues to innovate in the field of medical research. His work has garnered attention for its potential to improve treatment options for patients suffering from diabetic maculopathy.

Collaborations

Some of his notable coworkers include Noriaki Kato and Kaori Taniko, who have contributed to his research endeavors.

Conclusion

Hiroshi Nagano's innovative work in developing therapeutic agents for diabetic maculopathy showcases his commitment to advancing medical science. His contributions are vital in providing new treatment options for patients affected by this condition.